在免疫治疗领域,PD-1抑制剂曾一统天下近十年,却始终未能突破自身疗效的天花板。当辉瑞宣布以最高60亿美元的交易,将三生制药的PD-1/VEGF双抗纳入囊中时,市场为之大震。这不仅创造了近期双抗交易的金额高峰,更释放出一个明确信号:辉瑞已押注下一代免疫治疗标准。辉瑞董事长兼CEO Albert Bourla在近期高盛全球医疗健康会议上,毫不掩饰对该产品的信心:“在PD-1药物主导市场的十年间,这是...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.